BRAF Mutation Analysis (V600E), Tumor
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
As an adjunct to HNPCC / Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen, when colon tumor demonstrates microsatellite instability (MSI-H) and loss of MLH1 protein expression, to help distinguish a somatic versus germline event prior to performing expensive germline testing
As an adjunct to negative MLH1 germline testing in cases where colon tumor demonstrates MSI-H and loss of MLH1 protein expression
Note: Mayo's preferred screening test (MLBRF / MLH1 Hypermethylation and BRAF Mutation Analyses) includes both MLH1 promoter hypermethylation and BRAF V600E testing.
To identify colon tumors with a previously negative KRAS mutation analysis result that may respond to epidermal growth factor receptor-targeted therapies.
To identify melanoma tumors that may respond to anti-BRAF targeted therapies. Note, this is a laboratory developed test and has not been FDA-approved for this purpose.
Additional Tests Lists test(s) that are always performed, at an additional charge, with the initial test(s)
|Test ID||Reporting Name||Available Separately||Always Performed|
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
When this test is ordered, slide review will always be performed at an additional charge.
See Hereditary Nonpolyposis Colorectal Cancer Testing Algorithm in Special Instructions.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
BRAF Mutation Analysis(V600E),Tumor